Posted in Clinical Data ACC 2026: Meta-analysis supports CagriSema as superior first-line therapy in obesity April 2, 2026 Pharmaceutical Technology KOLs note that CagriSema could cannibalise semaglutide’s market share in obesity due to its improved weight loss and HbA1c reduction efficacy. Clinical DataMetabolic & GLP-1Read full story